Cullinan Therapeutics
Manufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1 Main St Ste 1350, Cambridge, Massachus...Phone Number
(617) 410-4650Website
www.cullinantherapeutics.comRevenue
-Stock Symbol
CGEMIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Cullinan Therapeutics
Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optiRead more
Cullinan Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cullinan Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Cullinan Therapeutics launches new products
Earning: See what the market has to say on Cullinan Therapeutics recently announced quarterly report
Check if Cullinan Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Cullinan Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Check out if Cullinan Therapeutics is spiking on competitors!
Cullinan Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Cullinan Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Cullinan Therapeutics
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Cullinan Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Cullinan Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Cullinan Therapeutics.
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Hiring Plans
Cullinan Therapeutics has more open roles in Medical & Health than it has had at any time in the past 12 months. Areas of expertise include: Clinical Trial Protocols, Biostatistics, Cell Therapy, Medical Monitoring, Medical Oncology, Clinical Practices, and Hematology.
Hiring Plans
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
Cullinan Therapeutics News & Media
Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
CAMBRIDGE, Mass., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, SeptemCullinan Therapeutics, Inc. (CGEM) Shareholder/Analyst Call Transcript
Cullinan Therapeutics, Inc. (CGEM) Shareholder/Analyst Call September 14, 2026 8:00 AM EDTCompany ParticipantsNicholas Smith - Head of Investor...Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
Company to host a virtual event today at 8:00 a.m. ET Company to host a virtual event today at 8:00 a.m. ETCullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
Results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC to be presented in Presidential Symposium 2 on Sunday, September 13, 2026
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cullinan Therapeutics
Sign Up For FreeTo access detailed company insights
Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific... Read More
